← Back to Search

Monoclonal Antibodies

JNJ-77242113 for Plaque Psoriasis (FRONTIER 1 Trial)

Phase 2
Waitlist Available
Research Sponsored by Janssen Research & Development, LLC
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 24 weeks
Awards & highlights

Summary

This trial is testing a new medication for plaque psoriasis to see how well it works.

Eligible Conditions
  • Plaque Psoriasis

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 24 weeks
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 24 weeks for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Percentage of Participants Achieving Psoriasis Area Severity Index (PASI) 75 Score at Week 16
Secondary outcome measures
Serum albumin, bovine
Change from Baseline in PASI Total Score at Week 16
Change from Baseline in PSSD Signs Score at Week 16
+12 more

Trial Design

6Treatment groups
Experimental Treatment
Placebo Group
Group I: Group 5: JNJ-77242113 Dose 3 BID and PlaceboExperimental Treatment2 Interventions
Participants will receive JNJ-77242113 Dose 3 BID and placebo from Week 0 through Week 16. Participants will receive placebo to maintain the blinding of dose regimens.
Group II: Group 4: JNJ-77242113 Dose 1 Twice Daily (BID) and PlaceboExperimental Treatment2 Interventions
Participants will receive JNJ-77242113 Dose 1 BID and placebo from Week 0 through Week 16. Participants will receive placebo to maintain the blinding of dose regimens.
Group III: Group 3: JNJ-77242113 Dose 3 QD and PlaceboExperimental Treatment2 Interventions
Participants will receive JNJ-77242113 Dose 3 QD and placebo from Week 0 through Week 16. Participants will receive placebo to maintain the blinding of dose regimens.
Group IV: Group 2: JNJ-77242113 Dose 2 QD and PlaceboExperimental Treatment2 Interventions
Participants will receive JNJ-77242113 Dose 2 QD and placebo from Week 0 through Week 16. Participants will receive placebo to maintain the blinding of dose regimens.
Group V: Group 1: JNJ-77242113 Dose 1 Once Daily (QD) and PlaceboExperimental Treatment2 Interventions
Participants will receive JNJ-77242113 Dose 1 QD and placebo from Week 0 through Week 16. Participants will receive placebo to maintain the blinding of dose regimens.
Group VI: Group 6: PlaceboPlacebo Group1 Intervention
Participants will receive placebo BID from Week 0 through Week 16.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Placebo
1995
Completed Phase 3
~2670
JNJ-77242113
2022
Completed Phase 2
~640

Find a Location

Who is running the clinical trial?

Janssen Research & Development, LLCLead Sponsor
980 Previous Clinical Trials
6,384,038 Total Patients Enrolled
Janssen Research & Development, LLC Clinical TrialStudy DirectorJanssen Research & Development, LLC
749 Previous Clinical Trials
3,960,692 Total Patients Enrolled
~75 spots leftby Jul 2025